Promestriene Affects <i>GREB</i>1 Expression in Estrogen Sensitive Breast Cancer Cells

• 作者: Alvin J. O. Almodovar David A. Decker Sally A. Litherland Xiang Zhu
• 来源期刊: 癌症治疗(英文)
• 学科: 医学
• 关键词: Breast Cancer SURVIVOR ESTROGEN Receptor Positive HORMONE Therapy Side Effects Promestriene
• 年，卷（期）: 2015,（9）
• 页码范围: 767-772
• 页数: 6页
• 分类号: R73

摘要

Promestriene (3-propyl ethyl, 17B-methyl estradiol) is a synthetic estrogen analogue with reported minimal systemic absorption which has been suggested for topical treatment of vaginal atrophy. Promestriene’s ability to stimulate proliferation and estrogen responsive gene expression was analyzed in estrogen receptor (ER+) positive breast cancer cell lines MCF-7, T-47D, and BT-474 using CFSE flow cytometric analysis, and quantitative RT-PCR analysis of GREB1 RNA expression, an estrogen responsive gene involved in estrogen receptor alpha expression. In estrogen replete conditions, Promestriene did not stimulate proliferation even at high concentrations (100,000 pg/ml). However, anti-estradiol depletion allowed low dose Promestriene (2 - 10 pg/ml) to stimulate GREB1 expression in all three cell lines at levels equal to that induced by estradiol (BT-474) or significantly higher than estradiol (MCF7 and T-47D). These findings suggest that Promestriene has the potential to support estrogen like cell signaling, a possible contraindication for use in treatment of vaginal atrophy associated with breast cancer aromatase inhibitor therapy.